ART Regimen Effective, Led to Less Weight Gain in Treatment-Naive HIV
(MedPage Today) -- A treatment regimen anchored by doravirine worked as well as a dolutegravir-based approach but led to significantly less weight gain among patients starting antiretroviral therapy (ART) for HIV, an open-label randomized trial...
A trial comparing two HIV treatments found that a regimen anchored by doravirine resulted in less weight gain compared to a dolutegravir-based approach, according to research presented at the International AIDS Conference. Conducted among 600 treatment-naive patients in South Africa, the study showed that 89% of those who took doravirine, lamivudine, and tenofovir disoproxil fumarate achieved undetectable HIV levels at 48 weeks, matching the 90.7% rate of those taking dolutegravir, emtricitabine, and tenofovir alafenamide.
While both regimens caused weight gain, the median weight increase was smaller with the doravirine-based regimen (3.0 kg) compared to the dolutegravir-based approach (5.0 kg). The doravirine regimen, however, was associated with greater bone mineral density loss. The researchers caution that while this alternative regimen prevents weight gain, it should not replace standard ART, as viral suppression remains the primary goal.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
